Hi,
I'm french so I use AI to translate my opinion about this company, of course NFA :
Carvolix develops AI-guided autonomous mini-robots and biomimetic implants (such as the Kalios mitral ring and the Epygon mitral valve). These technologies aim to automate complex procedures like heart valve replacement or stroke treatment, potentially revolutionizing access to advanced care by reducing reliance on human expertise and improving precision.
The positive elements :
The TAVIPILOT platform has already received FDA approval (July 2025), and its commercialization in the U.S. began in 2026, marking a major milestone for the company
Carvolix is also preparing to submit an FDA application for the Kalios mitral ring in 2026, with promising clinical results for other products like the Epygon mitral valve and the Artus urinary sphincter
The company was formed by merging three French players (Affluent Medical, Caranx Medical, Artedrone), backed by Truffle Capital (a specialist biotech/medtech fund) and a €10 million investment from Edwards Lifesciences, a sector leader
Carvolix is pursuing a strategic transformation to become a global leader in medical robotics and cardiovascular implants, with a clear ambition: **to democratize access to complex procedures** through AI and robotics.
For me, the strongest point is the CEO’s statement about the company’s future: he wants to remain independent and therefore refuses all M&A operations.